Ocular Therapeutix: Redefining the Retina Experience

Jeffrey S. Heier, MD
Chief Scientific Officer,
Ocular Therapeutix, Inc.

Retina Future Forum at APVRS | Gold Coast, Australia

The following presentation discusses OTX-TKI, an investigational product candidate that has not been approved by the FDA or any other regulatory body; safety and effectiveness have not been established

OCULAR THERAPEUTIX

Retina experience redefined

OTX-TKI: Axitinib via Hydrogel Allows for Tunable Sustained Release

AXITINIB

Multi-target Tyrosine Kinase Inhibitor (TKI)

Highly selective pan VEGF inhibitor[1]
Highly potent TKI[2]

+

HYDROGEL TECHNOLOGY

Bioresorbable, Sustained Drug Delivery



Proprietary hydrogel
Versatile, biocompatible, tunable platform[3]

OTX-TKI

is being developed with the aim to provide:

- **A single hydrogel insert**[3,4]
- **Continuous and consistent delivery up to 12 months**[3,5]
- **Complete and predictable bioresorption**[3,5]

OTX-TKI is an investigational product candidate which has not been approved by the FDA or any regulatory authority.

OCULAR THERAPEUTIX Retina experience redefined™

1. Zhao Y, et al. *Oncologist.* 2015;20(6):660-673. 2. Gross-Goupil M, et al. *Clin Med Insights Oncol.* 2013;7:269-277. 3. Blizzard CD, et al. Ocular Implant Containing a Tyrosine Kinase Inhibitor. US Patent 11,439,592 B2. September 13, 2022. 4. Tan CS, et al. *Clin Ophthalmol*. 2022;16:917-933. 5. Data on File 033. Ocular Therapeutix. 2026.
TKI, Tyrosine Kinase Inhibitor; VEGF, Vascular Endothelial Growth Factor

Study Design: OTX-TKI and Aflibercept Direct Comparison

SOL-1

Key Enrollment Criteria (Screening)

- Treatment naïve
- **BCVA ≥54 ETDRS letters** (~20/80)
- **CSFT of ≤500 µm**

Key Randomization Criteria (Day 1)

- **BCVA gain ≥10 ETDRS letters**
  OR
  BCVA ≥84 ETDRS letters (~20/20)
- **CSFT of ≤350 µm**

Proportion of subjects who maintained visual acuity, defined as <15 ETDRS letters of BCVA loss from baseline at Week 36



Baseline (Randomization) Study Eye Characteristics	OTX-TKI 0.45 mg N = 172†	Aflibercept 2 mg N = 172
Mean (SD) BCVA, ETDRS letter score, Snellen Equivalent	80.8 (7.6) ~20/25	79.2 (7.9) ~20/25
Mean (SD) CSFT, µm,	219.3 (37.1)	226.8 (42.1)

OCULAR THERAPEUTIX Retina experience redefined

*No aflibercept injection is given at baseline;
†Two OTX-TKI subjects were misrandomized, did not receive study treatment and were not included in the full analysis set
ClinicalTrials.gov. identifier: NCT06223958
Rescue Criteria: BCVA loss ≥15 ETDRS letters from baseline due to nAMD; or New macular hemorrhage that would likely lead to irreversible vision loss if left untreated in the opinion of the investigator after discussion with Medical Monitor
BCVA, best-corrected visual acuity; CSFT, central subfield thickness; ETDRS, Early Treatment Diabetic Retinopathy Study; SD, standard deviation

OTX-TKI Successfully Met Superiority Primary Endpoint

SOL-1

Vision Maintenance* with a Single Injection of OTX-TKI at Week 36



18.3%
Observed difference

Clear benefit† with OTX-TKI vs Aflibercept 2 mg

0.0006
P value

Exceptionally high statistical significance bolsters confidence in results

- OTX-TKI 0.45 mg (n=170)
- Aflibercept 2 mg (n=172)

OCULAR THERAPEUTIX Retina experience redefined™

*Vision maintenance defined as <15 ETDRS letters of loss.
† 18.3% observed difference of vision maintainers at week 36 in OTX-TKI vs Aflibercept arm, 17.5% risk difference
ETDRS, early treatment diabetic retinopathy

Significantly Lower Risk of Rescue During Year 1 with OTX-TKI



Time to First Rescue Treatment

OTX-TKI 0.45 mg (n=170)
Aflibercept 2 mg (n=172)

Rescue-free subjects include those who did not require rescue injections as specified by the protocol
*Nominal P value

Significantly Lower Risk of Rescue During Year 1 with OTX-TKI



Time to First Rescue Treatment

~6 Month Difference

OTX-TKI Week 52 rescue rate reflects ***~6-month*** **advantage** over aflibercept

No approved wet AMD intravitreal therapy has ≥6-month dosing label

OTX-TKI 0.45 mg (n=170)
Aflibercept 2 mg (n=172)

Rescue-free subjects include those who did not require rescue injections as specified by the protocol
*Nominal P value
AMD, age-related macular degeneration

OTX-TKI was Generally Well Tolerated

Ocular Adverse Events in the Study Eye

Subjects with Ocular AEs (> 2%) Through Week 52, n (%)	OTX-TKI 0.45 mg n = 170	Aflibercept 2 mg n = 172
Vitreous floaters	21 (12.4)	2 (1.2)
Cataract	12 (7.1)	5 (2.9)
Conjunctival hemorrhage	11 (6.5)	5 (2.9)
Retinal hemorrhage	10 (5.9)	17 (9.9)
Dry eye	7 (4.1)	2 (1.2)
Vitreous detachment	7 (4.1)	3 (1.7)
Punctate keratitis	6 (3.5)	0
Vitreous opacities	6 (3.5)	0
Eye pain	5 (2.9)	1 (0.6)
Anterior chamber opacity	4 (2.4)	0
Posterior capsule opacification	4 (2.4)	6 (3.5)

Safety is Essential in Wet AMD

No cases of endophthalmitis, occlusive or non-occlusive retinal vasculitis

AE, adverse event; AMD, age-related macular degeneration

Incidence of Macular Atrophy in SOL-1

SOL-1

Any Macular Atrophy[1]



Macular Atrophy in the Central 1mm[1]



OCULAR THERAPEUTIX Retina experience redefined™

[1]cRORA measured by the reading center

cRORA, complete retinal pigment epithelium and outer retinal atrophy

Single Injection of OTX-TKI Demonstrated Superiority to a Single Injection of Aflibercept (2 mg) in SOL-1

SOL-1 Results Highlight OTX-TKI's Groundbreaking Profile

First Phase 3 trial to demonstrate durability out to >9 months

~75% of OTX-TKI subjects were rescue free at Week 36

Unmatched Durability

Up to 52 Week visual & anatomic stability

On average, subjects maintained visual & anatomical outcomes with a single OTX-TKI injection

Sustained Disease Control

Well-tolerated safety profile

No cases of endophthalmitis, vasculitis through Week 52

Well-Tolerated

OCULAR THERAPEUTIX Retina experience redefined™

Maintenance of vision defined as proportion of subjects who maintain visual acuity, a loss of <15 ETDRS letters of from baseline
Rescue-free subjects include those who did not require rescue injections as specified by the protocol
ETDRS, early treatment diabetic retinopathy

OTX-TKI Development Program Summary

OTX-TKI

First & Only Agent with Novel Mechanism to Demonstrate Superiority to Anti-VEGF in a Phase 3 nAMD Trial

Unmatched Durability

Sustained Disease Control

nAMD Program

PHASE 3
Superiority Trial

Durability of a single OTX-TKI injection

Primary endpoint met

SOL-1

PHASE 3
Non-Inferiority Trial

Repeat dosing every 6 months

Randomization complete - topline data expected in Q1 '28

SOL-R

DR Program

PHASE 3
Superiority Trial

Evaluating yearly dosing

Enrollment in HELIOS-3 is underway

HELIOS-3

OCULAR THERAPEUTIX Retina experience redefined

DR, diabetic retinopathy; nAMD, neovascular age-related macular degeneration; VEGF, vascular endothelial growth factor;